Isomorphic raises $2.1B to push AI-designed drugs toward clinic

DeepMind spinout Isomorphic Labs raised $2.1 billion as Demis Hassabis now points to first AI-designed drugs entering human trials by late 2026.

何が変わったか

The company uses IsoDDE, a pipeline combining structure prediction, molecule generation, binding prediction and ADMET assessment.

Thrive, Alphabet-linked funds, MGX, Temasek and a UK sovereign AI fund joined the round, showing the capital intensity of AI drug discovery.

なぜ重要か

Entering clinical trials is not the same as approval; the pharmaceutical probability game remains slow and harsh.

次に見るべき点

見るべきなのは見出しの数字だけではなく、その製品、契約、プラットフォーム転換が今後2四半期で再現性を持つかどうかだ。

参考資料: CocoLoop